Results 1 to 10 of about 10,858,974 (235)
Some of the next articles are maybe not open access.

External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort

Annals of Surgical Oncology, 2021
9563 Background: Talimogene Laherparepvec (T-VEC) is a genetically modified herpes simplex type 1 virus and known as an effective oncolytic immunotherapy for injectable cutaneous, subcutaneous, and nodal melanoma lesions in stage IIIB-IVM1a patients. Recently, Stahlie et al.
Emma H. A. Stahlie   +3 more
openaire   +2 more sources

Economic evaluation of the combination of talimogene laherparepvec (T-vec) plus ipilimumab (T-vec+Ipi) versus ipilimumab (Ipi) in patients (pts) with advanced unresectable melanoma.

Journal of Clinical Oncology, 2018
e21545Background: A recent trial comparing T-vec+Ipi vs Ipi found no differential benefit in progression-free survival (PFS) (HR 0.83, 95%CI 0.56–1.23), but noted objective response rates (ORR) of ...
Abdulaali Almutairi   +5 more
openaire   +1 more source

Talimogene laherparepvec (T-VEC) as a treatment for melanoma: A systematic review

Journal of Oncology Pharmacy Practice
Background and aims Melanoma now presents an average risk of 1 in 50 in the Western world. Talimogene laherparepvec (T-VEC), an FDAapproved oncolytic virus derived from Herpes Simplex Virus type 1 (HSV-1), has proven effective in reducing morbidity and mortality from melanoma but causes adverse effects like ...
Sai Santhosha Mrudula Alla   +10 more
openaire   +2 more sources

An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions

American Journal of Clinical Dermatology, 2020
Talimogene laherparepvec (T-VEC) is the first agent approved for cancer in the emerging class of oncolytic viral therapies. While T-VEC was approved for the treatment of advanced melanoma in 2015, clinical utilization has been hampered by rapid changes in the therapeutic landscape of melanoma related to advances in both immune checkpoint blockade and ...
Cecilia A. Larocca   +3 more
openaire   +2 more sources

Successful Treatment of In-Transit Metastatic Melanoma in a Renal Transplant Patient With Combination T-VEC/Imiquimod Immunotherapy

Journal of Immunotherapy, 2020
In the era of immunotherapy for cancer, solid organ transplant patients who go on to develop metastatic or locally advanced melanoma offer particularly difficult challenges. New approaches are needed for these patients. We present a case of in-transit metastatic melanoma in a renal transplant patient.
Joel C, Sunshine   +3 more
openaire   +2 more sources

A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with metastatic sarcoma.

Journal of Clinical Oncology, 2018
11516Background: T-VEC is an oncolytic immunotherapy derived from HSV type-1 that is modified to selectively replicate within tumors and produce GM-CSF.
Ciara Marie Kelly   +18 more
openaire   +1 more source

ASO Author Reflections: Validation of Prediction Model for Response to Treatment with T-VEC

Annals of Surgical Oncology, 2022
Emma H. A. Stahlie   +1 more
openaire   +2 more sources

Exanthem nach einmaliger Injektion von T‐VEC

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2019
Daniel, Wagenknecht   +3 more
openaire   +2 more sources

Rash after a single injection of T‐VEC

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2019
Daniel Wagenknecht   +3 more
openaire   +1 more source

Home - About - Disclaimer - Privacy